Drugs / Vorinostat
last change 17 days ago re-read 2 minutes ago

Vorinostat

Small molecule targets HDAC1, HDAC2, HDAC3, HDAC6, NPC1, VHL via inhibition / restoration

Developed for
non-small cell lung carcinoma · plasma cell myeloma · lymphoma · myelodysplastic syndrome · HIV infectious disease · mantle cell lymphoma · cancer of unknown primary site · acute myeloid leukemia
+241 more · Burkitt lymphoma · Hodgkins lymphoma · neuroblastoma · breast cancer · chronic lymphocytic leukemia/small lymphocytic lymphoma · large-cell immunoblastic lymphoma · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation · glioblastoma · grade III lymphomatoid granulomatosis · MALT lymphoma · nodal marginal zone B-cell lymphoma · adult glioblastoma · chronic myelomonocytic leukemia · gliosarcoma · male breast carcinoma · splenic marginal zone lymphoma · acute lymphoblastic leukemia · acute myeloid leukemia, t(16;16)(p13.1;q22) · anaplastic large cell lymphoma · extranodal nasal NK/T cell lymphoma · female breast carcinoma · giant cell glioblastoma · graft versus host disease · leukemia · primary cutaneous B-cell lymphoma · Waldenstrom macroglobulinemia · acute erythroid leukemia · acute megakaryoblastic leukemia in adult · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with minimal differentiation · acute myelomonocytic leukemia M4 · acute promyelocytic leukemia · adult acute monocytic leukemia · angioimmunoblastic T-cell lymphoma · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · follicular lymphoma · intraocular lymphoma · leukemia, myeloid, accelerated-phase · myeloproliferative neoplasm, unclassifiable · neoplasm · oropharynx squamous cell carcinoma · primary cutaneous T-cell lymphoma · renal cell carcinoma · small intestine lymphoma · acute myeloid leukemia, inv(16)(p13.1;q22) · adult acute lymphoblastic leukemia · adult T-cell leukemia/lymphoma · anaplastic astrocytoma · brain cancer · brain neoplasm · cancer · childhood cerebral astrocytoma · childhood medulloblastoma · colorectal cancer · diffuse large B-cell lymphoma · esophageal cancer · gastric cancer · high grade malignant neoplasm · hypopharynx squamous cell carcinoma · malignant pancreatic neoplasm · mycosis fungoides and variants · myelodysplastic syndrome with excess blasts · pancreatic adenocarcinoma · pineoblastoma · prostate adenocarcinoma · refractory malignant neoplasm · supratentorial primitive neuroectodermal tumor · testicular lymphoma · acquired polycythemia vera · acute myeloid leukemia, t(15;17)(q24;q21) · anaplastic oligodendroglioma · atypical chronic myeloid leukemia, BCR-ABL1 negative · atypical teratoid rhabdoid tumor · breast carcinoma · castration-resistant prostate carcinoma · central nervous system teratoma · childhood brain stem glioma · childhood central nervous system germinoma · childhood central nervous system mixed germ cell tumor · childhood cerebellar astrocytic neoplasm · childhood choroid plexus neoplasm · childhood oligodendroglioma · childhood spinal cord tumor · chronic myeloid leukemia · classic Hodgkin lymphoma · craniopharyngioma · diffuse intrinsic pontine glioma · essential thrombocythemia · hepatosplenic T-cell lymphoma · invasive breast carcinoma · juvenile myelomonocytic leukemia · laryngeal squamous cell carcinoma · liver cancer · lung cancer · medulloepithelioma · melanoma · metastatic malignant neoplasm in the brain · metastatic neoplasm · metastatic squamous cell carcinoma · mixed glioma · mixed phenotype acute leukemia · myelodysplastic syndrome with multilineage dysplasia · myelodysplastic syndrome with ring sideroblasts · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · non-Hodgkin lymphoma · optic pathway glioma · oral cavity squamous cell carcinoma · ovarian carcinoma · paraganglioma · pediatric CNS choriocarcinoma · peripheral T-cell lymphoma, not otherwise specified · post-transplant lymphoproliferative disease · primary myelofibrosis · prostate cancer · refractory plasma cell neoplasm · sarcoma · small cell lung carcinoma · small intestine cancer · soft tissue sarcoma · subependymal giant cell astrocytoma · T-cell non-Hodgkin lymphoma · therapy related acute myeloid leukemia and myelodysplastic syndrome · urinary bladder cancer · urothelial carcinoma · uveal melanoma · Wilms tumor · yolk sac tumor of central nervous system · acute basophilic leukemia · acute megakaryoblastic leukemia · adult nodular lymphocyte predominant Hodgkin lymphoma · Alzheimer disease · anal canal cancer · anus cancer · B-cell adult acute lymphocytic leukemia · B-cell chronic lymphocytic leukemia · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · B-cell non-Hodgkin lymphoma · bladder transitional cell carcinoma · brain stem glioma · breast neoplasm · central nervous system neoplasm · cerebellar astrocytoma · cervical cancer · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · childhood brain meningioma · childhood ependymoma · childhood malignant neoplasm · chronic eosinophilic leukemia · chronic neutrophilic leukemia · clear cell renal carcinoma · colon adenocarcinoma · Crohn disease · Cushing disease due to pituitary adenoma · endometrial stromal tumor · ependymoblastoma · epilepsy · erythroleukemia · Ewing sarcoma · fallopian tube cancer · germ cell tumor · grade II meningioma · grade III meningioma · hairy cell leukemia · head and neck cancer · head and neck squamous cell carcinoma · hepatoblastoma · high grade B-cell lymphoma · Hodgkin's lymphoma, lymphocytic depletion · Hodgkin's lymphoma, lymphocytic-histiocytic predominance · Hodgkin's lymphoma, mixed cellularity · human papillomavirus-related squamous cell carcinoma · iris melanoma · large B-cell lymphoma · larynx verrucous carcinoma · leiomyosarcoma · major salivary gland cancer · major salivary gland carcinoma · malignant colon neoplasm · malignant epithelial tumor of ovary · malignant peripheral nerve sheath tumor · malignant pleural mesothelioma · marginal zone lymphoma · medium/large size posterior uveal melanoma · medullary thyroid gland carcinoma · medulloblastoma · mycosis fungoides · myelodysplastic syndrome with excess blasts-1 · nasopharyngeal carcinoma · Niemann-Pick disease, type C1 · nodular sclerosis classical Hodgkin lymphoma · ocular melanoma with extraocular extension · ovarian cancer · ovarian neoplasm · paranasal sinus squamous cell carcinoma · pediatric infratentorial ependymoma · pediatric supratentorial ependymoma · penile cancer · periampullary adenocarcinoma · peritoneum cancer · Pitt-Hopkins syndrome · plasma cell neoplasm · plasmablastic lymphoma · precursor B-cell acute lymphoblastic leukemia · precursor lymphoblastic lymphoma/leukemia · precursor T-cell acute lymphoblastic leukemia · primary central nervous system lymphoma · primary effusion lymphoma · primary mediastinal large B-cell lymphoma · primary peritoneal carcinoma · prostate carcinoma · rectal carcinoma · rectum adenocarcinoma · renal pelvis/ureter urothelial carcinoma · Rett syndrome · rhabdomyosarcoma · salivary gland adenoid cystic carcinoma · salivary gland squamous cell carcinoma · schizophrenia · Sezary syndrome · sickle cell disease · skin neoplasm · squamous cell lung carcinoma · T-cell adult acute lymphocytic leukemia · T-cell large granular lymphocyte leukemia · thyroid gland papillary carcinoma · tongue carcinoma · triple-negative breast carcinoma · undifferentiated carcinoma of nasopharynx · upper aerodigestive tract neoplasm · urinary bladder neoplasm · uterine carcinosarcoma · verrucous carcinoma of oral cavity · von Hippel-Lindau disease · vulva cancer · acute myeloid leukemia with multilineage dysplasia · myelodysplastic/myeloproliferative disease
Investigated by
Merck Sharp & Dohme LLC · National Cancer Institute (NCI) · M.D. Anderson Cancer Center · University of Washington · Celgene Corporation · Millennium Pharmaceuticals, Inc.
+165 more · National Institute of Allergy and Infectious Diseases (NIAID) · University of North Carolina, Chapel Hill · City of Hope Medical Center · Fred Hutchinson Cancer Center · Masonic Cancer Center, University of Minnesota · Memorial Sloan Kettering Cancer Center · Dana-Farber Cancer Institute · H. Lee Moffitt Cancer Center and Research Institute · National Comprehensive Cancer Network · Bayer · Brigham and Women's Hospital · Genentech, Inc. · Johns Hopkins All Children's Hospital · Milton S. Hershey Medical Center · New Approaches to Neuroblastoma Therapy Consortium · Ohio State University Comprehensive Cancer Center · Roswell Park Cancer Institute · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · University of California, San Francisco · University of Michigan Rogel Cancer Center · Virginia Commonwealth University · Weill Medical College of Cornell University · Yale University · Columbia University · Endeavor Health · Fox Chase Cancer Center · Groupe Francophone des Myelodysplasies · Hackensack Meridian Health · Jubilant DraxImage Inc. · Massachusetts General Hospital · Massey Cancer Center · National Institute of Neurological Disorders and Stroke (NINDS) · National Institutes of Health (NIH) · Northwestern University · OHSU Knight Cancer Institute · Samsung Medical Center · St. Jude Children's Research Hospital · Stanford University · The Methodist Hospital Research Institute · The University of Texas Health Science Center at San Antonio · Tiziana Marangon · UNC Lineberger Comprehensive Cancer Center · United Therapeutics · University of Southern California · Unravel Biosciences, Inc. · Washington University School of Medicine · AIDS Malignancy Consortium · Albert Einstein College of Medicine · Alberta Children's Hospital · Armando Santoro, MD · Arnold Palmer Hospital for Children · Asan Medical Center · AstraZeneca · Avon Foundation · Baylor College of Medicine · Baylor Health Care System · Bayside Health · Boston Children's Hospital · Brain Tumor Trials Collaborative · Brighton and Sussex University Hospitals NHS Trust · Case Comprehensive Cancer Center · Central and North West London NHS Foundation Trust · Chelsea and Westminster NHS Foundation Trust · Children's Hospital Colorado · Children's Hospital Medical Center, Cincinnati · Children's Hospitals and Clinics of Minnesota · Children's Mercy Hospital Kansas City · Cooper Human Systems · Copenhagen University Hospital at Herlev · Dartmouth-Hitchcock Medical Center · Duke University · ERA-NET · Emory University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · all 171 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) ZOLINZA 2009-09-23 fda.gov
Approved US (FDA) ZOLINZA 2006-10-06 fda.gov

Trials 261 · started per year

today
US approved 2006
1
1
1
2
27
21
17
27
37
28
17
15
8
6
9
7
9
4
4
4
2
2
4
4
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT06693284 Nov 2025 → Jan 2027 expected malignant peripheral nerve sheath tumor University of Minnesota Recruiting No outcome recorded
Phase 0 NCT03022565 Jan 2020 uveal melanoma University of Miami Withdrawn No outcome recorded
Phase 0 NCT03263533 Apr 2017 → Feb 2019 schizophrenia Virginia Commonwealth University Withdrawn No outcome recorded
Phase 1105 trials
Phase 1 NCT07150013 Mar → Dec 2026 expected Rett syndrome Unravel Biosciences, Inc. Recruiting No outcome recorded
Phase 1 NCT07150026 Mar → Dec 2026 expected Pitt-Hopkins syndrome Unravel Biosciences, Inc. Recruiting No outcome recorded
Phase 1 NCT07217379 Oct 2025 → Dec 2026 expected HIV infectious disease University of North Carolina, Chapel Hill Recruiting No outcome recorded
Phase 1 NCT05700630 Jul 2024 HIV infectious disease, immunodeficiency disease Masonic Cancer Center, University of Minnesota Withdrawn No outcome recorded
Phase 1 NCT03878524 Apr → Dec 2020 acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 OHSU Knight Cancer Institute Terminated No outcome recorded
Phase 1 NCT03742245 Jun 2019 → Dec 2025 overdue breast carcinoma The Methodist Hospital Research Institute Active not recruiting No outcome recorded
Phase 1 NCT03843528 May 2019 → Jul 2027 expected juvenile myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome Johns Hopkins All Children's Hospital Active not recruiting No outcome recorded
Phase 1 NCT03803605 Feb 2019 → Jan 2021 HIV infectious disease University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 1 NCT03332667 Sep 2018 → Feb 2024 neuroblastoma New Approaches to Neuroblastoma Therapy Consortium Completed No outcome recorded
Phase 1 NCT03426891 Mar 2018 → Oct 2021 brain neoplasm, glioblastoma H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded
Phase 1/258 trials
Phase 1/2 NCT03842696 Feb 2020 → Jul 2025 overdue acute leukemia, diffuse large B-cell lymphoma, follicular lymphoma, graft versus host disease +3 University of Michigan Rogel Cancer Center Active not recruiting No outcome recorded
Phase 1/2 NCT03167437 Oct 2017 → Jun 2035 expected Crohn disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 1/2 NCT03198559 Aug 2017 → Apr 2019 HIV infectious disease University of Melbourne Terminated No outcome recorded
Phase 1/2 NCT02589145 Jun 2016 → Apr 2019 lymphoma M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 1/2 NCT02836548 Jun 2016 → Nov 2023 melanoma, skin neoplasm The Netherlands Cancer Institute Completed No outcome recorded
Phase 1/2 NCT02638090 Mar 2016 → Jan 2024 overdue non-small cell lung carcinoma H. Lee Moffitt Cancer Center and Research Institute Active not recruiting No outcome recorded
Phase 1/2 NCT02553460 Jan 2016 → May 2022 overdue acute lymphoblastic leukemia St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 1/2 NCT02538510 Oct 2015 → Sep 2019 major salivary gland carcinoma, metastatic squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma, nasopharyngeal carcinoma University of Washington Completed No outcome recorded
Phase 1/2 NCT02475915 Jan → Nov 2015 SEARCH Research Foundation Completed No outcome recorded
Phase 1/2 NCT02124083 Apr 2014 → Dec 2016 Niemann-Pick disease, type C1 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed No outcome recorded
Phase 282 trials
Phase 2 NCT07261241 Jul 2026 → Jul 2030 expected neuroblastoma New Approaches to Neuroblastoma Therapy Consortium Not yet recruiting No outcome recorded
Phase 2 NCT06995521 Jul 2026 → Jun 2028 expected graft versus host disease Sung Won Choi Not yet recruiting No outcome recorded
Phase 2 NCT05608369 Jun → Aug 2025 human papillomavirus-related squamous cell carcinoma, hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma +1 Case Comprehensive Cancer Center Withdrawn No outcome recorded
Phase 2 NCT04339751 Apr 2025 Cushing disease due to pituitary adenoma National Institute of Neurological Disorders and Stroke (NINDS) Withdrawn No outcome recorded
Phase 2 NCT06145633 Sep 2024 → Dec 2026 expected castration-resistant prostate carcinoma, prostate adenocarcinoma Fred Hutchinson Cancer Center Recruiting No outcome recorded
Phase 2 NCT04220008 Oct 2021 Burkitt lymphoma, T-cell non-Hodgkin lymphoma, high grade B-cell lymphoma M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 2 NCT04190056 Mar 2021 → Jun 2023 breast cancer University of California, San Francisco Terminated No outcome recorded
Phase 2 NCT04357873 Oct 2020 → Dec 2022 anus cancer, cervical cancer, head and neck squamous cell carcinoma, penile cancer +2 UNICANCER Completed No outcome recorded
Phase 2 NCT03561259 Oct 2019 → Dec 2023 neuroblastoma Jubilant DraxImage Inc. Unknown No outcome recorded
Phase 2 NCT03894826 Dec 2018 → Apr 2020 epilepsy University of Calgary Unknown No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT01236560 Jan 2011 → Jun 2023 brain stem glioma, childhood cerebellar astrocytic neoplasm, childhood cerebral astrocytoma, childhood spinal cord tumor National Cancer Institute (NCI) Completed No outcome recorded
Phase 2/3 NCT00473889 May 2007 → Dec 2008 non-small cell lung carcinoma Merck Sharp & Dohme LLC Terminated No outcome recorded
Phase 34 trials
Phase 3 NCT01802333 Feb 2013 → Jun 2017 acute myeloid leukemia National Cancer Institute (NCI) Completed No outcome recorded
Phase 3 NCT00773747 Dec 2008 → Sep 2011 plasma cell myeloma Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 3 NCT00128102 Jun 2005 → Jul 2011 lung cancer, malignant pleural mesothelioma Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 3 NCT01386398 lymphoma European Organisation for Research and Treatment of Cancer - EORTC Withdrawn No outcome recorded
Phase not applicable5 trials
NCT01720602 Nov 2012 → Mar 2015 male breast carcinoma University of Washington Completed No outcome recorded
NCT01695057 Oct 2012 → Oct 2014 female breast carcinoma, triple-negative breast carcinoma University of Southern California Withdrawn No outcome recorded
NCT01342757 Dec 2010 → May 2012 adult glioblastoma, brain neoplasm, depressive disorder National Cancer Institute (NCI) Completed No outcome recorded
NCT01153672 Nov 2010 → Jul 2012 male breast carcinoma University of Washington Completed No outcome recorded
NCT00735826 Mar 2009 → Jul 2012 esophageal cancer, head and neck cancer, lung cancer, upper aerodigestive tract neoplasm Dartmouth-Hitchcock Medical Center Completed No outcome recorded
Phase not stated2 trials
NCT01838187 neuroblastoma, paraganglioma, pheochromocytoma Children's Hospital Medical Center, Cincinnati No longer available No outcome recorded
NCT00419367 primary cutaneous T-cell lymphoma Merck Sharp & Dohme LLC No longer available No outcome recorded
Also used as a comparator or background therapy in 16 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT05317403 Background Mar 2023 → Jan 2027 expected acute myeloid leukemia Medical College of Wisconsin Recruiting No outcome recorded
Phase 1 NCT03259503 Background Sep 2019 → Nov 2025 Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT03263936 Background Jul 2017 → Jul 2020 acute myeloid leukemia Therapeutic Advances in Childhood Leukemia Consortium Completed No outcome recorded
Phase 1 NCT00331513 Comparator Mar 2006 → Jan 2010 acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with multilineage dysplasia, acute myeloid leukemia with t(8;21)(q22;q22) translocation +5 National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT05848687 Background Nov 2023 → Dec 2028 expected acute lymphoblastic leukemia Tanja Andrea Gruber Recruiting No outcome recorded
Phase 1/2 NCT01983969 Background Nov 2013 → Nov 2017 cancer of unknown primary site, lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT01353482 Comparator malignant pleural mesothelioma University College, London Withdrawn No outcome recorded
Phase 26 trials
Phase 2 NCT02943642 Comparator May 2026 mycosis fungoides Virogen Biotechnology Inc. Withdrawn No outcome recorded
Phase 2 NCT03713320 Comparator Apr 2019 → Oct 2020 mycosis fungoides miRagen Therapeutics, Inc. Terminated No outcome recorded
Phase 2 NCT02559778 Comparator Sep 2015 → Sep 2030 expected neuroblastoma Giselle Sholler Recruiting No outcome recorded
Phase 2 NCT02035137 Comparator Jul 2014 → Feb 2021 neuroblastoma New Approaches to Neuroblastoma Therapy Consortium Completed No outcome recorded
Phase 2 NCT01550224 Comparator May 2013 → Nov 2014 acute myeloid leukemia with 11q23 abnormalities Steven E. Coutre Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03117751 Background Mar 2017 → Sep 2026 expected lymphoblastic leukemia, acute, with lymphomatous features St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT01728805 Comparator Nov 2012 → Mar 2017 primary cutaneous T-cell lymphoma Kyowa Kirin, Inc. Completed No outcome recorded
Phase 3 NCT01554852 Comparator May 2010 → Dec 2021 plasma cell myeloma University of Leeds Unknown No outcome recorded

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 287 sources stand behind the page.

FieldValueCited text
Known as vorinostat “This protocol will investigate the use of vorinostat (suberoylanilide hydroxamic acid - SAHA) in combination with infusional 5-FU and leucovorin for the treatment of metastatic...” NCT00336141
276

“Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers” NCT00537121

Vorinostat (suberoylanilide hydroxamic acid \[SAHA\]) is a small-molecule inhibitor of histone deacetylase (HDAC)” NCT01027676

“MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months” NCT00097929

“Vismodegib, and/or VorinostatNCT02788201

Vorinostat (Zolinza)” NCT00939991

NCT00121277

NCT00091559

NCT00126451

NCT00994500

NCT00641706

NCT00744354

NCT00005634

NCT00838929

NCT00702572

NCT00867178

NCT01174199

NCT03742245

NCT02042989

NCT00217412

NCT01554852

NCT00642954

NCT03212989

NCT00691210

NCT00992446

NCT02316340

NCT01502085

NCT00958074

NCT00632931

NCT03509207

NCT00253630

NCT00357708

NCT01110876

NCT01567709

NCT01153672

NCT01413750

NCT00882206

NCT03263533

NCT01019850

NCT02108002

NCT02475915

NCT00942266

NCT01294670

NCT01281176

NCT00831493

NCT00416130

NCT00262834

NCT00702962

NCT00423449

NCT01353482

NCT02707900

NCT00839956

NCT01267240

NCT00392353

NCT00673153

NCT01790568

NCT00455351

NCT02419755

NCT01720602

NCT00227513

NCT00937495

NCT00486720

NCT00788112

NCT01236560

NCT00336063

NCT07217379

NCT01522976

NCT00251589

NCT02349867

NCT01064921

NCT01365065

NCT00357305

NCT00589472

NCT03713320

NCT01738646

NCT00635791

NCT02589145

NCT00667082

NCT00787527

NCT02538510

NCT00111813

NCT00305773

NCT00750178

NCT01276717

NCT01076530

NCT00719875

NCT01578343

NCT00537121

NCT00138203

NCT03263936

NCT03878524

NCT01593670

NCT01600742

NCT00045006

NCT01297764

NCT00138177

NCT00424775

NCT01534260

NCT03382834

NCT00258349

NCT01169532

NCT04220008

NCT00662311

NCT02836548

NCT01084057

NCT01120834

NCT00132002

NCT00785798

NCT01378481

NCT01319383

NCT00132028

NCT03022565

NCT03842696

NCT00132067

NCT01208454

NCT01879085

NCT00363883

NCT02559778

NCT03561259

NCT01187446

NCT00910000

NCT01608139

NCT05700630

NCT07150026

NCT00268385

NCT07150013

NCT00574587

NCT00373490

NCT00601718

NCT00481078

NCT00918723

NCT00561418

NCT00875745

NCT00121225

NCT01023737

NCT00776503

NCT00499811

NCT00106626

NCT00858234

NCT00735826

NCT06145633

NCT01130506

NCT00816283

NCT00918489

NCT02420613

NCT01059552

NCT00762255

NCT00983268

NCT01118975

NCT00365599

NCT04357873

NCT01087554

NCT00479232

NCT00857324

NCT00331955

NCT03803605

NCT00331513

NCT00818649

NCT02553460

NCT03050450

NCT04190056

NCT00127101

NCT01748240

NCT03150329

NCT01189266

NCT02035137

NCT01394354

NCT02619253

NCT00127127

NCT00127140

NCT01695057

NCT01492881

NCT02412475

NCT00764517

NCT00330161

NCT00134043

NCT02943642

NCT01038388

NCT01045538

NCT01501370

NCT03056495

NCT03117751

NCT00875056

NCT00946673

NCT00895934

NCT00419367

NCT01116154

NCT00731952

NCT00275080

NCT00720876

NCT00667615

NCT00731731

NCT00503971

NCT05317403

NCT00243100

NCT01175980

NCT01132911

NCT01802333

NCT03426891

NCT00798720

NCT01342757

NCT03332667

NCT00821951

NCT00948064

NCT00368875

NCT01720875

NCT03167437

NCT00555399

NCT00238303

NCT01266057

NCT00972478

NCT00729118

NCT03894826

NCT01421173

NCT00697476

NCT01838187

NCT00907738

NCT01249443

NCT00772798

NCT05608369

NCT00972842

NCT02336074

NCT01587352

NCT01617226

NCT00948688

NCT02638090

NCT00278330

NCT00837174

NCT04339751

NCT03259503

NCT00278395

NCT01039363

NCT00565227

NCT00771472

NCT01550224

NCT00810602

NCT00656617

NCT01075113

NCT00128102

NCT00810576

NCT01789255

NCT02395627

NCT05848687

NCT00976183

NCT01386398

NCT00801151

NCT01500538

NCT01000155

NCT03198559

NCT01312818

NCT06693284

NCT02124083

NCT00109109

NCT07261241

NCT04308330

NCT00616967

NCT02083250

NCT00473889

NCT00287937

NCT02151721

NCT01422499

NCT01194427

NCT01983969

NCT00324870

NCT03843528

NCT01483690

NCT00310024

NCT00773747

NCT00324740

NCT01339871

NCT01728805

NCT00773838

NCT00324480

NCT00703664

NCT06995521

NCT01193842

NCT01266031

Known as IVORI “Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.” PMID 25552401 Jan 2015
Known as MK0683 MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months” NCT00109109
6

“Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma” NCT00419367

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months” NCT00091559

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)” NCT00126451

“Drug: vorinostat (MK0683 )” NCT00750178

NCT00866762

NCT00097929

Known as MSK390 “Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies” NCT00045006
Known as N-hydroxy-N'-phenyl-octanediamide N-hydroxy-N'-phenyl-octanediamide (Vorinostat)” NCT03056495
Known as NSC 701852 “A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma” NCT01587352
Known as NSC-748799 ChEMBL registry synonym — accepted as the source's own label CHEMBL98
Known as NSC-759852 ChEMBL registry synonym — accepted as the source's own label CHEMBL98
Known as SAHA “Determine the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) of vorinostat (SAHA) when administered continuously with standard doses of irinotecan...” NCT00537121
19

“This protocol will investigate the use of vorinostat (suberoylanilide hydroxamic acid - SAHA) in combination with infusional 5-FU and leucovorin for the treatment of metastatic...” NCT00336141

“The initial 15-20 patients (in the solid tumor or multiple myeloma or lymphoma stratum) receive suberoylanilide hydroxamic acid (SAHA) IV over 2 hours on day 1 of week 0 and...” NCT00045006

“Vorinostat (suberoylanilide hydroxamic acid [SAHA]) is a small-molecule inhibitor of histone deacetylase (HDAC) and induces cell differentiation, cell cycle arrest, and...” NCT02151721

“The first of these compounds, suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza), was recently approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma.” NCT01422499

“Vorinostat or SAHA (suberoylanilide hydroxamic acid) has been FDA approved for the treatment of refractory cutaneous T-cell lymphomas and has also shown activity in other lymphomas.” NCT00837174

“Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL).” PMID 19817748 Sep 2009

“Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).” NCT02336074

“A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma” NCT03509207

“Patients receive oral vorinostat (SAHA) once daily in the absence of disease progression or unacceptable toxicity.” NCT01386398

“Vorinostat (suberoylanilide hydroxamic acid \[SAHA\]) is a small-molecule inhibitor of histone deacetylase (HDAC)” NCT01027676

“MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months” NCT00109109

“Patients receive oral vorinostat (SAHA) once or twice daily and oral capecitabine twice daily on days 1-14.” NCT00121277

“we uncovered vorinostat (Zolinza™; suberanilohydroxamic acid, SAHA) as a potent anti-seizure agent.” PMID 29373639 Mar 2018

“Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor” PMID 24636848 Mar 2014

“MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months” NCT00091559

“Vorinostat or SAHA, a potent inhibitor of histone deacetylase (HDAC) activity” NCT00416130

“Drug: Vorinostat (SAHA)” NCT07150026

“Vorinostat (SAHA)” NCT01132911

“Vorinostat (SAHA)” NCT07150013

Known as suberanilohydroxamic acid “we uncovered vorinostat (Zolinza™; suberanilohydroxamic acid, SAHA) as a potent anti-seizure agent.” PMID 29373639 Mar 2018
Known as suberoylanilide hydroxamic acid “The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the...” NCT00128102
19

“This protocol will investigate the use of vorinostat (suberoylanilide hydroxamic acid - SAHA) in combination with infusional 5-FU and leucovorin for the treatment of metastatic...” NCT00336141

“Suberoylanilidehydroxamic acid (SAHA=vorinostat) is the most clinical advanced compound of the class and was approved by the US FDA in October 2006 for the treatment of...” PMID 22915450 Aug 2012

“Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in...” NCT01386398

“Vorinostat (suberoylanilide hydroxamic acid [SAHA]) is a small-molecule inhibitor of histone deacetylase (HDAC) and induces cell differentiation, cell cycle arrest, and...” NCT02151721

“The first of these compounds, suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza), was recently approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma.” NCT01422499

“Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers” NCT00537121

“Vorinostat or SAHA (suberoylanilide hydroxamic acid) has been FDA approved for the treatment of refractory cutaneous T-cell lymphomas and has also shown activity in other lymphomas.” NCT00837174

“This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue.” NCT01194427

“Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL).” PMID 19817748 Sep 2009

“Although histone deacetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disrupt HIV-1 latency in vitro” PMID 22837004 Jul 2012

“Vorinostat (also known as Suberoylanilide Hydroxamic Acid) is a new investigational drug that is not approved by the Food and Drug Administration.” NCT00565227

“The activity of histone deacetylase (HDAC) inhibitor, Vorinostat or Suberoylanilide hydroxamic acid (SAHA), against AML has been suggested” NCT01039363

Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.” NCT00045006

“A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma” NCT00720876

“Vorinostat (suberoylanilide hydroxamic acid \[SAHA\]) is a small-molecule inhibitor of histone deacetylase (HDAC)” NCT01027676

“Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor” PMID 24636848 Mar 2014

“MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months” NCT00091559

suberoylanilide hydroxamic acid (SAHA, Vorinostat)” NCT00365599

“oral vorinostat (suberoylanilide hydroxamic acid)” PMID 17145826 Dec 2006

Known as Suberoylanilide Hydroxamic acid (Vorinostat) Suberoylanilide Hydroxamic acid (Vorinostat)NCT01748240
Known as suberoylanilide hydroxamic acid - SAHA “Vorinostat (Zolinza, suberoylanilide hydroxamic acid - SAHA) a potent histone deacetylase, has recently been approved for clinical use for cutaneous T-cell lymphoma.” NCT00838929
3

“MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months” NCT00109109

“MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months” NCT00097929

“MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)” NCT00126451

Known as VOR “At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.” NCT02707900
1

“Drug: Vorinostat (VOR)” NCT03803605

Known as vorinostat (Zolinza) vorinostat (Zolinza)NCT00837174
2

Vorinostat (Zolinza)NCT01297764

Vorinostat (Zolinza)NCT00939991

Known as Vorinostat TM “Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in...” NCT01386398
Known as Vorinostat, MK 0683, SAHA Vorinostat, MK 0683, SAHANCT00801151
Known as Zolinza “The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide,...” NCT00787527
7

“Subjects are invited to participate in this study that will examine the use of three drugs called Sorafenib (Nexavar), Vorinostat (Zolinza) and Bortezomib (Velcade) for...” NCT01534260

“Vorinostat (suberoylanilide hydroxamic acid, SAHA, Zolinza) is a histone deacetylase inhibitor with clinical activity in cutaneous T-cell lymphoma (CTCL).” PMID 19817748 Sep 2009

Zolinza (vorinostat), vinorelbine” NCT00801151

zolinza/vorinostat” NCT01422499

ZolinzaNCT01075113

ZolinzaNCT00336063

ZolinzaNCT00392353

Known as Zolinza (vorinostat) Zolinza (vorinostat)NCT01500538
2

Zolinza (Vorinostat)NCT00875745

Zolinza (vorinostat)NCT01554852

Action Inhibit “blocking the enzymes necessary for cancer cell growth” NCT00045006
Modality Small molecule “Vorinostat is a small molecule inhibitor of class I and II histone deacetylases” PMID 24464266 Jan 2014
Route Intravenous “Patients receive suberoylanilide hydroxamic acid (SAHA) IV over 2 hours on days 1-3.” NCT00005634
Target VHL “Proteostasis modulation with vorinostat rescues missense mutated VHL protein.” PMID 37018064 Jun 2023